LG Chem helps the people to lead a healthy life by strengthening its R&D competence in Life Sciences.
Life Sciences is the company's new growth engine in the mid to long term goal. The company has secured the differentiated R&D competence and has received the U.S. FDA approval for its new drugs for the first time in Korea.
The company has actively penetrated into the overseas market and has expanded the pipelines for developing new drugs with active investment in R&D. The company is doing its best to become one of the best global pharmaceutical companies.
Sales
0.58KRW trillion
2018
0.63KRW trillion
2019
0.66KRW trillion
2020
  • 1984 Established Pharmaceuticals business division
  • 1991 Developed World’s first4th generation Cephalosporin
  • 2003 1st Korean NCE approved by USA FDA(Factive)
  • 2017 Merged with LG Life Sciences
Division
Primary Drug (PD) Primary Drug (PD)
Specialty Drug(SD) Specialty Drug(SD)
Aesthetic Aesthetic
R&D Pipeline
R&D Pipeline
Core Products
Eutropin Eutropin
Hyruan One Hyruan One
Zemiglo Zemimet SR Tab Zemiglo / Zemimet SR Tab
Eucept Eucept
YVOIRE YVOIRE